A pan-cancer analysis of the biological function and clinical value of BTLA in tumors

B and T-lymphocyte attenuator (BTLA) plays an immunosuppressive role by inhibiting T- B-cell functions. BTLA is associated with a variety of diseases, especially cancer immunity. However, the function in various cancers its clinical prognostic value have still not been comprehensively analyzed. This study aimed to identify relationship between from perspectives differences expression, value, immune infiltration, correlation immune-related genes cancers. Data regarding mRNA miRNA lncRNA data patients 33 existing were collected TCGA database. Target that interacts target obtained StarBase Based on bioinformatics analysis methods, types was thoroughly investigated, competing endogenous RNA network BTLA, miRNA, interacting constructed. The Kaplan-Meier (KM) (has-miR-137) completed using KM plotter. expression varied different cancers, statistical significance nine types. plotter analyze overall survival (OS) regression-free prognosis revealed statistically OS 11 out 21 cancers; 8 type also different. Correlation tumor positive gene (CTLA4 PDCD1) expression. Gene Set Enrichment Analysis showed co-expressed mainly act through biological processes pathways, including response regulation, cell surface receptor signaling pathway, antigen binding, receptor-mediated leukocyte migration. has potential as marker for CLL, COAD, NSCLC, OV diagnostic KIRC. close complex occurrence development tumors, immunotherapy worthy further analysis.